Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Kano trovafloxacin trial litigation Stories

2010-10-12 07:00:00

NEW YORK and BRISTOL, Tenn., Oct. 12 /PRNewswire-FirstCall/ -- Pfizer Inc.(NYSE: PFE) and King Pharmaceuticals, Inc. (NYSE: KG) today announced that they have entered into a definitive merger agreement. Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share, which represents a premium of approximately 40% to King's closing price as of October 11, 2010,...

2010-09-01 07:30:00

NEW YORK and CAMBRIDGE, Mass., Sept. 1 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO ) (Logo: http://photos.prnewswire.com/prnh/20100901/NY58014LOGO ) (Logo:...

2010-06-23 16:20:00

NEW YORK, June 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA). The worldwide suspension - which is effective immediately - follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement. To date, this adverse event has not been observed in...

2010-06-02 11:00:00

NEW YORK, June 2 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) and Epocrates, Inc., today announced a collaboration to give healthcare providers (HCPs) mobile access to the Pfizer Medical Information Group to obtain scientific answers to their product questions or to report an adverse event. For the first time, clinicians can make direct contact through the Epocrates drug reference app on their iPhone® device to pharmaceutical manufacturers and immediately apply...

2009-05-14 13:34:59

U.S. pharmaceutical giant Pfizer said it would offer free medication to eligible unemployed U.S. workers who had lost their health insurance. The company will call the program MAINTAIN, an acronym standing for Medicines Assistance for Those who Are In Need, the company said. We all know people who have been laid off recently and have lost their health insurance, making it difficult for them to pay for health care, said Pfizer Regional President of Worldwide Pharmaceuticals Dr. Jorge Puente in...

2009-01-31 15:18:53

A lawsuit by Nigerian families who say U.S. drugmaker Pfizer used their children in an illegal test of an experimental antibiotic can proceed, a court says. Reversing an earlier court finding that the suit must be heard in Nigeria, the U.S. Court of Appeals for the 2nd Circuit in New York ruled Friday that the suits can now go forward in the U.S. courts. Legal experts say the ruling could set a precedent affecting other American companies accused of wrongdoing overseas, The Washington Post...

3d1bcfd64b97c489fd4e919f145260741
2009-01-14 10:38:06

A Pfizer Inc. executive said as many as 800 researchers will be cut by the U.S.-based pharmaceutical company this year. The Wall Street Journal said the job cuts, which would equal 5 percent to 8 percent of the company's 10,000 research employees, will be made at Pfizer's labs worldwide. Martin Mackay, head of Pfizer's research and development, told the newspaper the cuts are part of a continuing effort to focus research work on treatments with the best chances of reaching the market. The...

2008-10-20 09:00:42

Pfizer has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory pain medication Bextra, which the company voluntarily withdrew from the US market in 2005. Additionally, following key court rulings in favor of Celebrex, claims regarding Celebrex, a pain treatment, will also be resolved as part of the settlement. The announcement follows favorable...

2008-10-17 09:00:27

Pfizer Inc announced today that it has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory (NSAID) pain medication Bextra, which Pfizer voluntarily withdrew from the U.S. market in 2005. Additionally, following key court rulings in favor of Celebrex, claims regarding Celebrex, an effective pain treatment for millions of patients, will also be resolved as...

2008-07-20 03:00:43

By Arnold, Matthew PFIZER FOLLOWED Eli Lilly's lead in posting a list of $10 million in grants and charitable contributions the company made to medical, scientific and patient organizations during the first quarter of 2008 as "part of an ongoing drive throughout the company to increase transparency." The disclosures include medical education grants, fellowship and scholarship support for institutions, grants to patient organizations, medical and scientific associations and academic or other...